Tirzepatide Shows Superior Weight Loss Efficacy Over Semaglutide in Real-World Study

A large-scale real-world study has demonstrated that tirzepatideView drug details provides significantly greater weight reduction than semaglutideView drug details in adults with overweight (search)Search disease or obesity (search)Search disease, with consistent benefits observed across various patient populations.

The research, conducted using Truveta (search)Search term Data from a collective of US healthcare systems, analyzed outcomes from 41,223 patients who initiated either tirzepatideView drug details (9,193 patients) or semaglutideView drug details (32,030 patients) between May 2022 and September 2023.

Superior Weight Loss Outcomes with Tirzepatide

After propensity score matching to balance baseline characteristics, researchers found that tirzepatideView drug details users were substantially more likely to achieve clinically meaningful weight loss milestones compared to those taking semaglutideView drug details.

Within one year of treatment, 81.8% of tirzepatideView drug details users achieved ≥5% weight loss versus 64.6% of semaglutideView drug details users. More impressive differences emerged at higher thresholds, with 62.1% of tirzepatide patients reaching ≥10% weight loss (compared to 38.0% with semaglutide) and 42.3% achieving ≥15% weight loss (versus just 19.3% with semaglutide).

"The hazard ratios comparing tirzepatideView drug details to semaglutideView drug details were 1.76 for 5% weight loss, 2.42 for 10% weight loss, and 3.04 for 15% weight loss, indicating substantially higher likelihood of achieving these clinically important thresholds with tirzepatide," the researchers noted.

Percentage Weight Reduction Over Time

The study also examined mean percentage changes in body weight at specific time points:

• At 3 months: -5.9% with tirzepatide vs. -3.6% with semaglutide
• At 6 months: -10.1% with tirzepatide vs. -5.9% with semaglutide
• At 12 months: -15.2% with tirzepatide vs. -7.9% with semaglutide

After adjusting for residual confounding factors, the absolute difference in weight loss between tirzepatideView drug details and semaglutideView drug details was -2.3% at 3 months, -4.3% at 6 months, and -7.2% at 12 months.

Consistent Benefits Across Patient Subgroups

The superior efficacy of tirzepatideView drug details remained consistent across different analytical approaches and patient populations. Notably, the benefits were observed in both patients with and without type 2 diabetes (search)Search disease (T2D (search)Search disease), though those without T2D experienced larger weight reductions overall with both medications.

"Treatment effects were consistent in direction and significance between methodological approaches and within the subgroup of patients with T2D (search)Search disease," the researchers stated.

Safety Profile Comparison

An important finding was the comparable safety profile between the two medications. No significant differences were observed in the risk of gastrointestinal adverse events, which are commonly associated with GLP-1 receptor agonists.

Gastroenteritis was the most common adverse event, occurring at rates of 21.0 and 19.1 cases per 1,000 person-years for tirzepatideView drug details and semaglutideView drug details, respectively. Other monitored adverse events included bowel obstruction, cholecystitis, cholelithiasis, gastroparesis, and pancreatitis.

Study Strengths and Limitations

The research represents the first real-world comparative effectiveness study of tirzepatideView drug details and semaglutideView drug details in adults with overweight (search)Search disease or obesity (search)Search disease. Its strengths include the large sample size, inclusion of patients who might be excluded from clinical trials (such as those with major depressive disorder), and the use of multiple analytical approaches to confirm findings.

However, the researchers acknowledged several limitations. Weight loss is directly observable to patients, which may result in informative censoring—patients seeing desired results might be more likely to continue treatment. Additionally, medication shortages during the study period may have affected discontinuation rates.

"While a modified intention-to-treat analysis inclusive of post-discontinuation weights showed smaller reductions in weight, differences between tirzepatideView drug details and semaglutideView drug details were similar," the researchers noted.

Clinical Implications

These findings align with existing evidence from randomized controlled trials (RCTs) while extending knowledge to real-world populations. The results suggest that tirzepatideView drug details may be a more effective option for weight management in clinical practice for patients with overweight (search)Search disease or obesity (search)Search disease, regardless of diabetes status.

The researchers emphasized that future work is needed to compare the effects of tirzepatideView drug details and semaglutideView drug details on other key endpoints, particularly cardiovascular outcomes. Additionally, they noted that studies comparing the higher-dose formulations specifically labeled for weight loss (rather than diabetes) would be valuable.

A head-to-head clinical trial comparing tirzepatideView drug details to semaglutideView drug details in patients with overweight (search)Search disease or obesity (search)Search disease without T2D (search)Search disease (SURMOUNT-5) is currently underway, with results expected in late 2024, which will provide further evidence on the comparative efficacy of these medications.